HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sven G Meuth Selected Research

Alemtuzumab (Campath)

3/2022A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab.
1/2022Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.
1/2021Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
1/2020A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.
1/2020Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
1/2020Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.
1/2020Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient.
12/2019Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.
8/2019Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.
1/2019Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sven G Meuth Research Topics

Disease

89Multiple Sclerosis
08/2022 - 11/2007
26Inflammation (Inflammations)
05/2022 - 08/2006
24Relapsing-Remitting Multiple Sclerosis
03/2022 - 02/2011
23Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
02/2022 - 09/2008
19Neuroinflammatory Diseases
11/2021 - 09/2013
19Stroke (Strokes)
01/2020 - 01/2009
14Demyelinating Diseases (Demyelinating Disease)
10/2022 - 11/2003
10Neoplasms (Cancer)
05/2022 - 01/2012
9Ischemic Stroke
01/2020 - 04/2011
8Disease Progression
07/2022 - 09/2008
8Progressive Multifocal Leukoencephalopathy
01/2021 - 01/2012
7Infections
08/2022 - 01/2012
7Brain Ischemia (Cerebral Ischemia)
02/2014 - 10/2009
6Autoimmune Diseases of the Nervous System
03/2022 - 07/2017
6Encephalitis (Encephalitis, Rasmussen)
03/2022 - 12/2011
6Primary angiitis of the central nervous system
02/2022 - 01/2018
6Hypoxia (Hypoxemia)
01/2021 - 05/2006
5Lymphopenia (Lymphocytopenia)
08/2022 - 11/2013
5Infarction (Infarctions)
03/2022 - 01/2009
5Ischemia
11/2019 - 09/2010
5Thrombosis (Thrombus)
10/2018 - 11/2012
5Central Nervous System Diseases (CNS Diseases)
02/2016 - 09/2009
4Absence Epilepsy (Childhood Absence Epilepsy)
10/2022 - 09/2007
4Limbic Encephalitis (Paraneoplastic Limbic Encephalitis)
03/2022 - 06/2016
4Epilepsy (Aura)
03/2022 - 09/2017
4Seizures (Absence Seizure)
03/2022 - 09/2017
4Neuromyelitis Optica (Devic's Disease)
01/2022 - 12/2016
4Rheumatoid Arthritis
05/2021 - 02/2011
4Leukocytosis (Pleocytosis)
06/2020 - 01/2020
4Atrophy
01/2019 - 07/2012
4Nervous System Diseases (Neurological Disorders)
05/2018 - 02/2009
4Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
06/2014 - 01/2009
3Virus Diseases (Viral Diseases)
02/2022 - 01/2021
3Glioma (Gliomas)
01/2022 - 05/2008
3Brain Diseases (Brain Disorder)
11/2021 - 06/2015
3Neurodegenerative Diseases (Neurodegenerative Disease)
09/2021 - 02/2014
3Alzheimer Disease (Alzheimer's Disease)
09/2021 - 07/2017
3Autoimmune Diseases (Autoimmune Disease)
05/2021 - 01/2016
3Deglutition Disorders (Dysphagia)
01/2021 - 01/2019
3Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
01/2021 - 09/2013
3Edema (Dropsy)
01/2021 - 08/2010
3Encephalomyelitis (Myeloencephalitis)
06/2020 - 07/2014
3Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
01/2020 - 01/2016
3Anti-N-Methyl-D-Aspartate Receptor Encephalitis
01/2019 - 07/2017
3Proteinuria
12/2018 - 01/2016
3Neuralgia (Stump Neuralgia)
01/2018 - 08/2006
2Torticollis (Wryneck)
11/2022 - 01/2022
2Paralysis (Palsy)
11/2022 - 03/2011
2Hippocampal Sclerosis
05/2022 - 10/2020
2Autoimmune limbic encephalitis
05/2022 - 12/2021
2Brain Neoplasms (Brain Tumor)
05/2022 - 11/2015

Drug/Important Bio-Agent (IBA)

22Alemtuzumab (Campath)FDA Link
03/2022 - 01/2012
19AntibodiesIBA
04/2022 - 11/2003
16Natalizumab (Tysabri)FDA Link
01/2021 - 02/2011
13Biomarkers (Surrogate Marker)IBA
10/2021 - 04/2011
12CytokinesIBA
10/2022 - 11/2003
12Proteins (Proteins, Gene)FDA Link
12/2021 - 05/2008
11Potassium Channels (Potassium Channel)IBA
07/2015 - 05/2008
9AutoantibodiesIBA
03/2022 - 01/2017
8CuprizoneIBA
10/2022 - 01/2016
8Myelin-Oligodendrocyte GlycoproteinIBA
02/2022 - 02/2010
8AntigensIBA
11/2021 - 05/2009
7Fingolimod Hydrochloride (FTY720)FDA Link
05/2022 - 11/2013
7Pharmaceutical PreparationsIBA
10/2021 - 09/2010
7Monoclonal AntibodiesIBA
01/2019 - 09/2008
6Rituximab (Mabthera)FDA Link
01/2022 - 12/2013
6Ion Channels (Ion Channel)IBA
05/2021 - 12/2011
5CladribineFDA LinkGeneric
08/2022 - 11/2020
5Glucose (Dextrose)FDA LinkGeneric
05/2022 - 04/2011
5Immunoglobulin G (IgG)IBA
01/2022 - 01/2016
5Retinaldehyde (Retinal)IBA
01/2022 - 09/2015
5Neuroprotective AgentsIBA
01/2020 - 11/2014
4Dimethyl FumarateIBA
02/2022 - 09/2018
4DNA (Deoxyribonucleic Acid)IBA
01/2021 - 01/2016
4CalciumIBA
11/2019 - 10/2009
4Peptides (Polypeptides)IBA
07/2014 - 08/2010
4KininsIBA
11/2012 - 08/2010
3Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA
03/2022 - 10/2020
3Protein Isoforms (Isoforms)IBA
03/2022 - 10/2020
3ocrelizumabIBA
01/2022 - 01/2021
3Reactive Oxygen Species (Oxygen Radicals)IBA
11/2021 - 09/2017
3Amyloid (Amyloid Fibrils)IBA
09/2021 - 06/2012
3HLA-DR Antigens (HLA-DR)IBA
01/2021 - 01/2015
3InterferonsIBA
12/2020 - 12/2018
3Oligoclonal BandsIBA
06/2020 - 01/2020
3Glutamic Acid (Glutamate)FDA Link
01/2020 - 09/2008
3Oxygen (Dioxygen)IBA
11/2019 - 01/2009
3N-acetyltalosaminuronic acid (NAT)IBA
01/2019 - 05/2017
3Blood Coagulation Factors (Coagulation Factor)IBA
01/2018 - 12/2016
3AcidsIBA
01/2017 - 05/2008
3Glatiramer Acetate (Copaxone)FDA Link
07/2014 - 01/2012
3Bradykinin Receptors (Bradykinin Receptor)IBA
09/2012 - 08/2010
2Hyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsIBA
10/2022 - 12/2013
2CationsIBA
06/2022 - 11/2014
2Chelating AgentsIBA
06/2022 - 01/2017
2ChemokinesIBA
05/2022 - 08/2006
2Membrane Proteins (Integral Membrane Proteins)IBA
05/2022 - 01/2018
2Glutamine (L-Glutamine)FDA Link
05/2022 - 01/2020

Therapy/Procedure

44Therapeutics
07/2022 - 11/2007
12Immunotherapy
05/2022 - 12/2008